The E1B-55K product from human adenovirus is a substrate of the small ubiquitin-related modifier (SUMO)-conjugation system. SUMOylation of E1B-55K is required to transform primary mammalian cells in cooperation with adenovirus E1A and to repress p53 tumour suppressor functions. The biochemical consequences of SUMO1 conjugation of 55K have so far remained elusive. Here, we report that E1B-55K physically interacts with different isoforms of the tumour suppressor protein promyelocytic leukaemia (PML). We show that E1B-55K binds to PML isoforms IV and V in a SUMO1-dependent and -independent manner. Interaction with PML-IV promotes the localization of 55K to PMLcontaining subnuclear structures (PML-NBs). In virusinfected cells, this process is negatively regulated by other viral proteins, indicating that binding to PML is controlled through reversible SUMOylation in a timely coordinated manner. These results together with earlier work are consistent with the idea that SUMOylation regulates targeting of E1B-55K to PML-NBs, known to control transcriptional regulation, tumour suppression, DNA repair and apoptosis. Furthermore, they suggest that SUMO1-dependent modulation of p53-dependent growth suppression through E1B-55K PML-IV interaction has a key role in adenovirus-mediated cell transformation.
Introduction
Cellular transformation of mammalian cells is a complex process involving the inhibition of tumour suppressor proteins (for example p53, pRB) and/or the overexpression of proto-oncogenes (for example, c-myc, ras) resulting in the deregulation of cell cycle and growth arrest. The pro-tumorigenic functions of the 55-kDa phosphoproteins encoded by the early region 1B (E1B-55K) of human adenoviruses are primarily linked to the modulation of the tumour suppressor p53 and consequently inhibition of programmed cell death and growth arrest. Subsequent steps of direct interaction (Sarnow et al., 1982a; Kao et al., 1990) , transcriptional repression (Yew et al., 1994; Berk, 1998, 1999) and nuclear-cytoplasmic relocalization (Endter et al., 2001 (Endter et al., , 2005 induce the complete silencing of p53-dependent tumour suppressive functions. However, previously described results suggest additional p53-independent mechanisms of E1B-55K induced cellular transformation involving cellular factors as Mre11 (Ha¨rtl et al., 2008) or the transcription factor Daxx (Sieber and Dobner, 2007) . Interestingly, most so far known interaction partners of E1B-55K are transient components of the nuclear promyelocytic leukaemia (PML) bodies (Van Damme et al., 2010) . The PML protein has first been described as the causal agent in acute promyelocytic leukaemia as a fusion with the RARa receptor generated by the chromosomal translocation t(15;17) (Ascoli and Maul, 1991; de The et al., 1991; Kakizuka et al., 1991; Chang et al., 1992; Goddard et al., 1992; Kastner et al., 1992; Pandolfi et al., 1992; Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994; Melnick and Licht, 1999; . Since these initial findings, it has become evident that PML is a general tumour suppressor frequently deregulated in various tumour types (Gurrieri et al., 2004) most presumably involving secondary effects of PML bodies as sites of protein degradation (Lallemand-Breitenbach et al., 2001) , transcriptional regulation (Li et al., 2000; Zhong et al., 2000) , cellular senescence (Ferbeyre et al., 2000; Pearson et al., 2000; Bischof et al., 2002; Langley et al., 2002) , tumour suppression (Salomoni and Pandolfi, 2002; Salomoni et al., 2008) , DNA repair (Bischof et al., 2001; Carbone et al., 2002) , apoptosis (Hofmann and Will, 2003; Takahashi et al., 2004) and epigenetic regulation (Torok et al., 2009) . Interestingly, functional inactivation of the E1B-55K leucine-rich nuclear export sequence (NES) induces enhanced posttranslational modification of E1B-55K by the small ubiquitin-related modifier 1 (SUMO1) at lysine 104 (SUMO-conjugation motif, SCM) as well as augments transformation of primary rat cells involving the accumulation of p53, E1B-55K and PML in subnuclear aggregates (Endter et al., 2001 (Endter et al., , 2005 . Consistently, mutational inactivation of the SCM completely abrogates the ability of E1B-55K to transform primary rodent cells in combination with E1A (Endter et al., 2001) . Although the role of E1B-55K SUMOylation is still unclear, several line of evidence indicates that this posttranslational modification regulates the targeting of E1B-55K to subnuclear structures and viral transcription/replication centers (Endter et al., 2005; Kindsmu¨ller et al., 2007) . Interestingly, PML as well as associated factors are suspected to mediate an intracellular viral defense mechanism and are targeted by multiple viral proteins during infection (Everett, 2001; Everett and Chelbi-Alix, 2007; Tavalai and Stamminger, 2008) . For closer analysis of the role of PML during adenoviral infection/transformation, we decided to use HAdV5 E1B-55K as a tool to study the relationship of viral proteins with these nuclear structures and a putative involvement of PML in viral-mediated oncogenesis.
Results

E1B-55K interacts and colocalizes with endogenous PML in transformed rodent cells
The HAdV5 E1B-55K is a multifunctional phosphoprotein that shuttles continuously between the cytoplasm and nucleus regulated in part by its NES and SCM (Kindsmu¨ller et al., 2007) . Mutational inactivation of the NES leads to the accumulation of the viral protein in the nucleus accompanied by sequestration of different cellular proteins including PML (Endter et al., 2001 (Endter et al., , 2005 Ha¨rtl et al., 2008) . To elucidate this phenomenon, stably transformed rat cell lines AB120/AB115 expressing E1A plus E1B-55K-wt/E1A plus E1B-55K-NES were analysed for steady-state localization of E1B-55K and PML (Figures 1A and B) . Consistent with the published results, E1B-55K-wt localizes in a large cytoplasmic accumulation in proximity to the nucleus (Figure 1Ad ) (Zantema et al., 1985a, b) , whereas PML exhibits a punctuate nuclear staining (Figure 1Ae ) (Endter et al., 2005) . However, on inhibition of the CRM1-mediated nuclear export by leptomycin B, E1B-55K-wt accumulates in several bright stained nuclear aggregates clearly colocalizing with endogenous PML in B70% of all cells examined (Figures 1Aj-Al) . Consistently, a comparable phenotype could be observed in the cell line AB115 in the majority of the cells (>90%) ( Figure 1B) . Correlating with the size of E1B-55K-NES nuclear accumulations, PML is sequestered in bright stained subnuclear aggregates (Figures 1Ba-Bc) , exhibiting a punctuate surrounding of globular E1B-55K-NES (Figures 1Bd-Bf; 5 Â enlarged areas). We further assayed for interaction of the viral protein with endogenous PML in these transformed rat cells (Figures 1C and D) . As described earlier (Stuurman et al., 1992) , immunoblotting for rat PML using mAb 5E10 shows a set of PML-specific bands with sizes ranging from 60 to 130 kDa ( Figure 1E ). Intriguingly, it seems that concurrent expression of E1A plus E1B-55K and/or transformation per se alters the observable PML expression pattern compared with BRK1 leading to remarkably higher levels of endogenous protein ( Figure 1E ). Although E1B-55K-wt shows no or only a partial colocalization in IF analysis ( Figure 1A ), E1B-55K-wt as well as E1B-55K-NES harbour the intrinsic capability to coprecipitate with endogenous rat PML ( Figure 1C ) in total cell lysates supporting the assumption that colocalization of E1B-55K with PML is mediated by direct or indirect interaction. Interestingly, the reverse experiment reveals coprecipitation of only two PML-corresponding bands at about 60 and 130 kDa ( Figure 1D ), indicating preferential binding of E1B-55K to a specific subset of PML protein. This together with the observation that E1B-55K-NES reorganizes PML-NBs ( Figure 1B ) and augments transformation of primary rodent cells (Endter et al., 2005) further indicates that binding of E1B-55K to PML may be critical for its transforming potential.
E1B-55K binds specifically to human PML-IV/V in transient-transfected H1299 cells The observable PML expression pattern varies considerably as a result of extensive regulation between cells of different tissues or mammalian species. Although human cell lines exhibit a complicated system expressing at least seven distinguishable PML isoforms (Jensen et al., 2001) , we decided to analyse the capability of E1B-55K to interact with the human orthologs of rodent PML as very less is known about the expression of distinct PML isoforms in rats. Therefore, we transfected H1299 cells with E1B-55K-wt and plasmids encoding for human PML isoforms I-VI. Direct immunoprecipitation of E1B-55K shows a sufficient and comparable amount of the adenoviral protein in all transfections ( Figure 2a, panel 1 ). Another band of B75 kDa was also evident most presumably corresponding to covalently SUMO1-modified E1B-55K (Figure 2a , panel 1) (Endter et al., 2001) . Interestingly, the analysis of coprecipitated flag-PML reveals a highly specific interaction of E1B-55K with the PML isoforms IV and V ( Figure 2a , panel 2, lane 6/7), whereas some minor interactions with the isoforms I and III are visible in long exposure (data not shown). Corresponding observations could be made by precipitating flag-tagged PML and subsequent staining for E1B-55K (Figure 2b , panel 1). Most interestingly, it seems that covalently SUMOylated E1B-55K could also be coimmunoprecipitated by PML-IV/V implying interaction with both E1B-55K species (Figure 2b , panel 2, lane 6/7). All these findings were validated in at least two independent experiments including a validation of our system by reproducing already published data concerning the binding of E4orf3 to PML-II (Hoppe et al., 2006; Leppard et al., 2009) . Taken together, these experiments show that E1B-55K exhibits high affinity to only two human PML isoforms.
Viral infection alters the affinity of E1B-55K for specific PML isoforms Previously published data illustrate that the adenoviral protein E4orf3 is necessary and sufficient to disrupt cellular PML bodies during adenoviral infection (Carvalho et al., 1995; Puvion-Dutilleul et al., 1995; Doucas et al., 1996) . As the E4orf3-mediated PML relocalization seems to be conserved among human adenoviruses (Stracker et al., 2005) , it has been proposed that this might be a general mechanism to counteract the antiviral capabilities of PML bodies (Ullman et al., 2007; Ullman and Hearing, 2008) . Interestingly, this activity might be exclusively dependent on the interaction of E4orf3 with PML-II (Hoppe et al., 2006; Leppard et al., 2009) . Detailed studies have revealed an astonishing amount of cross-talk between (Magnification Â 7600). (C-E) Immunoprecipitation of PML/E1B-55K was performed by using mAb 5E10 (a-PML)/mAb 2A6 (a-E1B-55K), resolved on 10% SDS-PAGE and visualized by immunoblotting. Coprecipitated proteins and input levels of total cell lysates were detected by using mAb 2A6 (a-E1B-55K), mAb 5E10 (a-PML) and mAB AC-15 (a-b-actin). All monoclonal rodent cell lines (BRK1, baby rat kidney; AB120/AB115, baby rat kidney cells stably expressing HAdV5 E1A and E1B-55K-wt/NES) used are derived from freshly prepared pBRK cells as described earlier (Nevels et al., 1997) . Specific PML bands are highlighted (*) and closer referred to in the text. Molecular weight in kDa is indicated on the left, whereas corresponding proteins are labelled on the right.
adenoviral proteins in the modulation of host cell factors as for example shown for p53 transcriptional activity in the presence of E1B-55K, E4orf3 and/or E4orf6 (Ko¨nig et al., 1999) . To evaluate whether other viral proteins interfere or alter the interaction of E1B-55K with PML-IV/V, H1299 cells were transfected with plasmids expressing human PML isoforms I to VI and superinfected with wild-type virus (H5pg4100). As suspected, the E1B-55K PML-binding pattern ( . Immunoprecipitation of E1B-55K/flag-PML was performed by using mAB 2A6 (a-E1B-55K)/mAB flag-M2 (a-flag), resolved on 10% SDS-PAGE and visualized by immunoblotting. Coprecipitated proteins and input levels of total cell lysates were detected by using mAb 2A6 (a-E1B-55K), mAb flag-M2 (a-flag) and mAb AC-15 (a-b-actin). Molecular weight in kDa is indicated on the left, whereas corresponding proteins are labelled on the right. Immunoprecipitation of E1B-55K was performed by using mAB 2A6 (a-E1B-55K), resolved on 10% SDS-PAGE and visualized by immunoblotting. Coprecipitated proteins and input levels of total cell lysates were detected by using mAb flag-M2 (a-flag), mAb 2A6 (a-E1B-55K) and mAB AC-15 (a-b-actin). Molecular weight in kDa is indicated on the left, whereas corresponding proteins are labelled on the right.
SUMOylation of E1B-55K regulates PML interaction P Wimmer et al
Mutational inactivation of the E1B-55K SCM abolishes subnuclear colocalization with endogenous PML during infection As inhibition of CRM1-mediated nuclear export by leptomycin B or equivalently mutational inactivation of the E1B-55K NES results in enhanced SUMO1 modification and relocalization to nuclear accumulations of the viral protein in rodent cells (Endter et al., 2001) , we analysed the E1B-55K PML localization during productive adenoviral infection. As PML expression is frequently deregulated in human tumour cell lines and/ or during oncogenesis Gurrieri et al., 2004; Scaglioni et al., 2006) , we analysed several human tumour and pseudoprimary cell lines for endogenous PML expression (Supplementary Figure 1) . Consequently, we decided to use human hepatocytic cells (HepaRG) (Gripon et al., 2002; Cerec et al., 2007) , as they express PML in the well-defined physiological amounts (Condemine et al., 2006) and represent a suitable system to analyse endogenously PML components during viral infection Lukashchuk and Everett, 2010) . Cells were infected with wild-type virus (H5pg4100), E1B-55K null mutant H5pm4149 (Kindsmu¨ller et al., 2009) or previously described H5pm4102/H5pm4101 virus harbouring mutations within the SCM (K104R)/NES (L83/87/91A) of E1B-55K (Kindsmu¨ller et al., 2007) . Representative results of IF analysis is shown in Figure 4A . As expected, PML is relocalized in virus-infected cells (Figures 4Ab, Ae, Ah, and Ak) by E4orf3 in so-called track-like structures (Carvalho et al., 1995; PuvionDutilleul et al., 1995; Doucas et al., 1996) , whereas E1B-55K shows a more complex localization pattern (Ornelles and Shenk, 1991) . However, a subpopulation of about 30% of infected HepaRG cells exhibit small nuclear accumulations of the viral protein (Figure 4Aa ). These E1B-55K aggregates colocalize with a fraction of redistributed PML protein in globular accumulations that do not impose the same track-like structures (Figures 4Aa-Ac) . In contrast, infection by H5pm4101 resulted in a complete accumulation of E1B-55K-NES within the nucleus of infected cells exhibiting a comparable phenotype concerning the localization of nuclear E1B-55K accumulations and PML in >80% of the cells (Figures 4Ag-Ai) . Consistent with our prior work, functional inactivation of the E1B-55K SCM completely abolishes the formation of E1B-55K positive nuclear accumulations (Kindsmu¨ller et al., 2007) and concomitantly colocalization with PML (Figures 4Aj-Al) . Although E1B-55K-K104R and E1B-55K-NES differ substantially in their steady-state localization ( Figure 4A ) (Kindsmu¨ller et al., 2007) both mutant proteins coprecipitated with PML in comparable amounts to E1B-55K-wt ( Figure 4B ). This suggests that these amino-acid exchanges do not abolish the intrinsic ability of E1B-55K to bind to endogenous PML during virus infection, as the protein complexes can form in total cell lysates containing proteins from both nuclear and cytoplasmic compartments. More importantly, we have previously shown that E1B-55K-K104R accumulates in the nuclear matrix fraction as efficiently as the E1B-55K-wt protein (Kindsmu¨ller et al., 2007) without forming E1B-55K positive nuclear condensations (Endter et al., 2001) . In sum, these results strongly support the idea that SCM-mediated subnuclear targeting of E1B-55K is essential for its colocalization with endogenous PML in Ad-infected human HepaRG cells.
Interaction of E1B-55K with PML-IV/V is regulated by distinct mechanisms involving modification by SUMO As it is well know that SUMOylation has an essential role in the formation of PML-NBs as well as in the recruitment/regulation of PML-NB-associated proteins (Shen et al., 2006; Van Damme et al., 2010) , we further analysed the involvement of E1B-55K SUMOylation on the PML-IV/V-binding capabilities of the adenoviral protein. Therefore, H1299 cells were transfected with plasmids encoding for E1B-55K-wt, E1B-55K-V103D, E1B-55K-K104R, E1B-55K-NES and alternatively human PML isoforms IV or V. Direct immunoprecipitation of E1B-55K shows a sufficient and comparable amount of the protein precipitated in all samples ( Figure 5a , panel 1). As expected, the SUMOylation of E1B-55K appears most prominent on mutation of the NES (Figure 5a , panel 1, lane 9/10), whereas no covalent modification was detected with E1B-55K-V103D/E1B-55K-K104R harbouring mutations within the c-K-x-E motif ( Figure 5a , panel 1, lane 5/6/7/8) (Endter et al., 2001 (Endter et al., , 2005 . As the SUMOylation-deficient mutants are substantially impaired to coimmunoprecipitate PML-IV ( Figure 5a , panel 2, lane 5/7) (Figure 5c ), we assume that SUMOylation of E1B-55K is a major determinant of binding to PML-IV. Intriguingly, E1B-55K PML-IV interaction is not exclusively dependent on the posttranslational modification as longer exposures reveal some residual amounts of coprecipitated PML-IV (data not shown), indicating that at least one other determinant is involved in this process. In contrast, PML-V coprecipitation seems to be mostly independent of E1B-55K SUMOylation, although some variations can be seen correlating with the protein input levels. These results are consistent with earlier data (Figure 4) , showing no observable difference in E1B-55K-K104R/ E1B-55K-NES coprecipitation by endogenous PML as PML-IV binding is not evident during infection (Figure 3 ) most presumably due to E4orf6 expression (Lethbridge et al., 2003) . In summary, we showed that the interaction of E1B-55K per se with PML-IV depends on SUMOylation of the viral protein, whereas binding to PML-V mainly occurs in a SUMO-independent manner.
Discussion
Over the last years, it has become evident that cellular PML bodies facilitate various functions in cell metabolism including cell differentiation (Salomoni, 2009) (Carvalho et al., 1995; Puvion-Dutilleul et al., 1995; Doucas et al., 1996) . Furthermore, PML bodies are proposed to mediate a general intracellular barrier for viral infections (Everett, 2001; Everett and ChelbiAlix, 2007; Tavalai and Stamminger, 2008) . Thus, it seems conclusive that adenoviruses evolved an E4orf3-dependent conserved mechanism to counteract this special PML-NB function (Stracker et al., 2005; Ullman et al., 2007; Ullman and Hearing, 2008) . Intriguingly, our data provide evidence of E1B-55K as an additional viral factor interacting with and/or modulating cellular PML bodies as well as associated proteins (Sieber and Dobner, 2007; Ha¨rtl et al., 2008) . Furthermore, these results in general offer a new perspective to deconstruct the complexity of Figure 4 Subnuclear colocalization of E1B-55K with endogenous PML during infection is dependent on a functional SCM motif. (A) Human hepatocytes (HepaRG) were infected with wild-type (H5pg4100) and mutant viruses (H5pm4149, H5pm4102, H5pm4101) at a multiplicity of 50 f.f.u. and fixed with methanol after 24 h p.i. Samples were double-labelled in situ with mAb 4E8 (a-E1B-55K) and pAb H-238 (a-PML). Primary antibodies were detected with Cy3-and fluorescein isothiocyanate-conjugated secondary antibodies, respectively. Representative a-E1B-55K (red; Aa, Ad, Ag, Aj) and a-PML (green; Ab, Ae, Ah, Ak) staining patterns of at least 50 analysed cells are shown. The overlays of the single images (merge) are shown in Ac, Af, Ai and Al. In all panels, nuclei are indicated by a dotted line, respectively. E1B-55K and PML positive nuclear accumulations are indicated by white arrows. (Magnification Â 7600) (B, C) Human hepatocytes (HepaRG) were infected with wild-type (H5pg4100) and mutant viruses (H5pm4149, H5pm4102, H5pm4101) at a multiplicity of 200 f.f.u., harvested after 36 h and total cell extracts were prepared. Immunoprecipitation of PML was performed by using pAb a-PML (Novus Biologicals) resolved on 10% SDS-PAGE and visualized by immunoblotting. Coprecipitated proteins and steady-state expression levels of total cell lysates were detected by using pAb H-238 (a-PML), mAb 2A6 (a-E1B-55K), mAb B6-8 (a-DBP) and mAB AC-15 (a-b-actin). Molecular weight in kDa is indicated on the left, whereas corresponding proteins are labelled on the right. Figure 5 E1B-55K interaction with PML-IV/V is dependent on different mechanisms involving posttranslational modification of the viral protein by SUMO. Subconfluent H1299 cells were transfected with 10 mg pE1B-55K-wt/V103D/-K104R/-NES and 10 mg of different lentiviral constructs alternatively encoding for N-terminal flag-tagged human PML isoforms IV/V and harvested after 48 h. (a, b) Immunoprecipitation of E1B-55K from the nuclear fraction (Lee et al., 1995) was performed by using mAB 2A6 (a-E1B-55K), resolved on 10% SDS-PAGE and visualized by immunoblotting. Coprecipitated proteins and steady-state expression levels of total cell lysates were detected by using mAb 2A6 (a-E1B-55K), mAb flag-M2 (a-flag) and pAb a-SAF-A. Molecular weight in kDa is indicated on the left, whereas corresponding proteins are labelled on the right. (c) The band intensities of coprecipitated PML-IV of (a) (panel 2) were quantified using the GeneSnap software (SynGene) and normalized to E1B-55K coprecipitated PML-IV (a, panel 2, lane 3).
SUMOylation of E1B-55K regulates PML interaction P Wimmer et al E1B-55K-mediated repression of the tumour suppressor protein p53 Berk, 1998, 1999; Ko¨nig et al., 1999) . Despite several studies, the molecular mechanism how E1B-55K represses p53 remains unknown possibly involving E1B-55K-mediated SUMOylation of p53 in the presence of cellular cofactors (Mu¨ller and Dobner, 2008) . However, as PML-IV is the only isoform so far described to recruit/modulate endogenous p53 (Fogal et al., 2000) , it is tempting to speculate that interaction of E1B-55K, p53 and PML-IV might be a key regulatory event to modify/repress p53 functions. We have previously shown that the transformation potential of E1B-55K is ultimately linked to SUMO1 conjugation (Endter et al., 2001 (Endter et al., , 2005 . Therefore, mutational inactivation of the E1B-55K SCM leads to the abolishment of E1B-55K-mediated transcriptional repression of p53 coupled with the complete loss of its transforming potential, whereas mutations enhancing E1B-55K SUMOylation (for example, E1B-55K-NES) exhibit the complete opposite phenotype. Furthermore, these functional consequences might also depend on the proper localization of E1B-55K in subnuclear aggregates sequestering p53 and PML (Endter et al., 2001 (Endter et al., , 2005 . These observations as well as our results linking PML-IV binding of E1B-55K to the posttranslational modification of the viral protein by SUMO (Figure 5) , further substantiate the assumption that E1B-55K PML-IV interaction might be essential for E1B-55K-mediated p53 modulation and thus cellular transformation. Unfortunately, it remains unclear, if the interaction of E1B-55K with PML is conserved among other human adenovirus serotypes comparably to E4orf3 (Stracker et al., 2005) . This possibility is nevertheless fascinating as it would offer a possible explanation for the different transformation capabilities of the large adenovirus E1Bs and earlier suggestions linking nuclear localization of HAdV5 E1B-55K (Endter et al., 2005) and presumably of subgroup HAdV12 E1B-54K (Kra¨tzer et al., 2000) to their oncogenic potential. However, it remains subject for further studies to evaluate how and whether E1B-55K facilitates PML and/or associated proteins to mediate its multiple functions during productive infection involving transcriptional repression of p53 (Yew et al., 1994; Berk, 1998, 1999) , selective protein degradation and viral mRNA transport in combination with E4orf6 Querido et al., 2001; Stracker et al., 2002; Baker et al., 2007; Dallaire et al., 2009) .
Intriguingly, the shift of PML binding during viral infection (Figure 3 ) compared with transient transfection (Figure 1 ) might be explained by earlier results linking the release of E1B-55K from the nuclear matrix to E4orf6-mediated de-SUMOylation of E1B-55K (Lethbridge et al., 2003) . These observations fit well in a model correlating the expression of E4orf6 with the reduction of posttranslationally modified E1B-55K (Lethbridge et al., 2003) and therefore the loss of SUMOylation-dependent PML-IV binding ( Figure 5 ) as well as nuclear-cytoplasmic relocalization (Figure 4) . Consequently, we observed no difference in E1B-55K-K104R/E1B-55K-NES coprecipitation from total cell lysates with endogenous PML during infection (Figure 4) , as E4orf6 expression drastically limits the amount of SUMOylated E1B-55K (Lethbridge et al., 2003) and consequently PML-IV interaction ( Figure 5 ). These results furthermore highlight that E1B-55K function synergistically involves proper localization, functional protein interaction domains and posttranslational modification as the intrinsic PML-binding capability in total cell lysates per se is not enough to achieve a specific subcellular localization (Figures 1 and 4) . This hypothesis in summary might also explain the involvement of SUMOylation in nuclear localization of E1B-55K, the relocalization of E1B-55K on expression of E4orf6 and the transient colocalization of E1B-55K with PML during very early stages of infection (Younghusband, 1985; Ornelles and Shenk, 1991; Carvalho et al., 1995; Doucas et al., 1996; Ko¨nig et al., 1999; Lethbridge et al., 2003; Endter et al., 2005) . The observation that multiple cellular pathways are extensively regulated by posttranslational modification through different SUMO isoforms despite only low amounts of detectable modified effector proteins currently represents one of the most inapprehensible questions perceptively termed the SUMO enigma (Hay, 2005) . Consistent observations have been made for the viral E1B-55K protein (Endter et al., 2001 (Endter et al., , 2005 Kindsmu¨ller et al., 2007) ; however, it remains fascinating that E1B-55K efficiently coprecipitates PML-IV despite the relatively low amount of SUMO modification (Figures 2a and 5a) as well as the observation that the majority of coprecipitated E1B-55K-wt appears to be not modified by SUMO (Figure 2b) . We currently favour an explanation suggested by Hay (2005) proposing SUMOylation to trigger the assembly of stable multiprotein complexes that continuously persist until reactivation, whereas SUMO is immediately deconjugated after establishment. However, we are also aware that the enormous amount of PML-associated proteins offer more possible/additional mechanisms to explain/ regulate E1B-55K PML functional interaction (Borden and Culjkovic, 2009; Van Damme et al., 2010) . Unfortunately, studying the functions of endogenous PML are frequently hampered by poor working antibodies and the dependency of PML expression on the used cell system (Supplementary Figure 1) (Lukashchuk and Everett, 2010) . Although our results indicate a general affinity of E1B-55K for human PML-IV/V as well as a specific subset of rat PML, which may represent the rat orthologs of these isoforms, it seems premature to draw a final conclusion of the exchangeability of results obtained in either of these two systems as no data are available concerning the expression of PML in rats (Supplementary Figure 1) . In this context, recent data concerning the organization of the murine pml locus underline the possibility of species-specific PML expression with partial homologous nevertheless considerably differing PML isoforms (Goddard et al., 1995; Condemine et al., 2006) . Ongoing studies are dedicated to reveal the molecular background of the isoform-specific E1B-55K PML interaction during infection (Figure 3 ) as E1B-55K per se only seems to be capable of binding to PML-IV/V (Figure 2) . In this context, it additionally remains completely elusive how the specificity of E1B-55K PML-IV/V interaction is achieved, as no unique protein sequences can be found in this two PML isoforms. Both harbour the exons 1-6, which are actually present in all PML proteins except for PML-VII, the exon 7a, which again is additionally present in PML-I/-II/-III, and their own unique C-terminus (Jensen et al., 2001) . However, as a similar phenomenon has been described for HPV E6 (Guccione et al., 2004) , it seems that disruption and/or facilitation of PML nuclear bodies, specific PML isoforms and/or PML-associated proteins may represent a general mechanism that might also have a role in viral-mediated oncogenesis.
Materials and methods
Cell lines and culture conditions
HepaRG (Gripon et al., 2002; Cerec et al., 2007) , MIO-M1 (Limb et al., 2002; Lawrence et al., 2007) , A549 (DSMZ ACC 107; Braunschweig, Germany), H1299 (Mitsudomi et al., 1992) , HEK293 (Graham et al., 1977) , U2OS (Ponten and Saksela, 1967) and primary BRK-derived cell lines (AB120, AB115) (Endter et al., 2005) were grown in DMEM supplemented with 10% FCS, 100 U of penicillin, 100 mg of streptomycin per ml in a 5% CO 2 atmosphere at 37 1C. For HepaRG cells, the medium was additionally supplemented with 5 mg/ml of bovine insulin and 0.5 mM of hydrocortisone.
Plasmids and transient transfections
HAdV5 E1B-55K-wt (Nevels et al., 2001) , the E1B mutant proteins E1B-55K-NES (L83/87/91A), E1B-55K-V103D and E1B-55K-K104R (Endter et al., 2001 (Endter et al., , 2005 were expressed from pcDNA3 vector. N-terminal flag-tagged human PML isoforms I-VI were expressed from pLKO.1-puro vector (kindly provided by R Everett). All PML isoforms are termed according to the nomenclature of Jensen et al. (2001) as PML-I (AAG50180), PML-II (AF230410), PML-III (S50913), PML-IV(AAG50185), PML-V (AAG50181) and PML-VI (AAG50184).
For transient transfection, subconfluent cells were treated with a mixture of DNA and 25 kDa linear polyethylenimine (Polysciences Inc., Eppelheim, Germany). One hour before transfection, the medium was removed and replaced by DMEM without antibiotics. The transfection solution was prepared by incubating a mixture of DNA, PEI and DMEM in a ratio of 1:10:100 for 30 min at room temperature. After application of the transfection solution, cells were incubated for 8 h before replacing the medium with standard culture medium.
Viruses
H5pg4100 served as wild-type HAdV5 virus , H5pm4102 and H5pm4101 carry mutations alternatively disrupting the SCM (H5pm4102) or the leucinrich NES (H5pm4101) of E1B (Kindsmu¨ller et al., 2007) . H5pm4149 carries stop codons in the E1B-55K open reading frame and does not express the E1B-55K protein (Kindsmu¨ller et al., 2009) . All viruses were propagated and titered as fluorescent forming units in HEK293 monolayer cultures .
Antibodies and protein analysis
Primary antibodies specific for Ad proteins used included E1B-55K mouse mAb 2A6 (Sarnow et al., 1982b) , E1B-55K rat mAb 7C11 (Kindsmu¨ller et al., 2009 ) and E1B-55K rat mAb 4E8 (Kindsmu¨ller et al., 2009) . Primary antibodies specific for cellular and epitopically expressed proteins included PML rabbit pAb H-238 (Santa Cruz Biotechnology, Inc., Heidelberg, Germany), PML rabbit pAb NB 100-59787 (Novus Biologicals, Ltd., Cambridge, UK), PML mouse mab 5E10 (Stuurman et al., 1992) , rabbit pAb a-SAF-A (Herrmann et al., 2005) , flag mouse mAb flag-M2 (Sigma-Aldrich, Inc., Mu¨nchen, Germany) and b-actin mouse mab AC-15 (SigmaAldrich, Inc.).
All protein extracts were prepared in full RIPA lysis buffer (50 mM Tris-HCl/pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM DTT, 0.1% sodium dodecyl sulphate, 1% Nonidet P-40, 0.1% Triton X-100, 0.5% sodium deoxycholate) containing 1% (v/v) PMSF, 0.1% (v/v) aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM DTT, 25 mM iodacetamide and 25 mM N-ethylmaleimide. Alternatively, cells were fractionated as described by Lee et al. (1995) before protein extracts of the nuclei were prepared in full RIPA buffer. For immunoprecipitation, protein A-sepharose (3 mg/i.p.) was coupled with 1 mg of flag-M2/100 ml mAb 2A6 for 1 h at 4 1C. The antibodycoupled protein A-sepharose was added to pansorbin-sepharose (50 ml/lysate; Calbiochem, Merck Chemicals Ltd., Nottingham, UK) precleared extracts and rotated for 2 h at 4 1C. Proteins bound to the antibody-coupled protein A-sepharose were precipitated by centrifugation, washed three times, boiled for 3 min at 95 1C in 2Â Laemmli buffer and analysed by immunoblotting. For immunoblotting of steady-state protein levels/immunoprecipitation solutions, equal amounts of total protein were separated by SDS-PAGE, transferred to nitrocellulose membranes (Schleicher and Schu¨ll/Whatman) and incubated as described earlier (Kindsmu¨ller et al., 2009) . The bands were visualized by enhanced chemiluminescence as recommended by the manufacturer (Pierce, Thermo Fisher Scientific, Bonn, Germany) on X-ray films (CEA RP, medical X-ray film). Autoradiograms were scanned and cropped using Adobe PhotoshopCS4, band intensities were determined by GeneSnap (SynGene, Cambridge, UK) and figures were prepared using Adobe IllustratorCS4 software.
Indirect immunofluorescence
For indirect immunofluorescence, cells were grown on glass coverslips as described recently (Endter et al., 2005) . Cells were fixed in ice-cold methanol at À20 1C for 15 min and permeabilized in PBS, 0.5% Triton X-100 for 30 min at room temperature. After 1 h blocking in TBS-BG buffer, coverslips were treated for 1 h with the primary antibody diluted in PBS, washed three times in PBS, 0.1% Tween 20 followed by incubation with the corresponding FITC-, Texas Red-or Cy3-conjugated secondary antibodies (Dianova, Hamburg, Germany). Coverslips were washed three times in PBS, 0.1% Tween 20, mounted in Glow medium (Energene, Regensburg, Germany) and digital images were acquired on a DM6000 fluorescence microscope with a charge-coupled device camera (Leica Microsystems, Wetzlar, Germany). Images were cropped using Adobe PhotoshopCS4 and assembled with Adobe IllustratorCS4.
